← Eichor
Condition: Myelodysplastic Anemia Synced from ClinicalTrials.gov · July 29, 2026

Recruiting studies: Myelodysplastic Anemia

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

MCW Alpha/Beta T-Cell and B-Cell Depletion With Targeted ATG Dosing
NA · 1 location(s) · Medical College of Wisconsin · NCT05794880Haplo-Cord HSCT for AML/MDS
NA · 4 location(s) · Fujian Medical University Union Hospital · NCT07588360A Study of Elritercept to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS
Phase 3 · 179 location(s) · Takeda · NCT06499285Safety and Feasibility of Sulforaphane to Promote Early Haematopoietic Recovery After Cord Blood Transplantation
NA · 1 location(s) · Institute of Hematology & Blood Diseases Hospital, China · NCT07297576Unrelated Umbilical Cord Blood Transplantation for Severe Aplastic Anemia and Hypo-plastic MDS Using CordIn(TM), Umbilic
Phase 1/Phase 2 · 1 location(s) · National Heart, Lung, and Blood Institute (NHLBI) · NCT03173937Long-term Safety and Tolerability of HSK39297 in Patients With Paroxysmal Nocturnal Hemoglobinuria
Phase 2 · 1 location(s) · Haisco Pharmaceutical Group Co., Ltd. · NCT06745622A Phase Ib, Multicenter, Open-Label Study of Multiple-Dose EA5 in Adults With Paroxysmal Nocturnal Hemoglobinuria (PNH)
Phase 1 · 2 location(s) · Shanghai Lanyi Therapeutics Co., Ltd. · NCT07256301Global PNH Patient Registry
Phase N/A · 1 location(s) · Aplastic Anemia and MDS International Foundation · NCT05755867Study to Assess the Pharmacokinetics, Safety, and Tolerability of Iptacopan in Pediatric PNH Patients
Phase 3 · 13 location(s) · Novartis Pharmaceuticals · NCT06934967Genetic Landscape in Women with Metastatic Ovarian Cancer Before and During Treatment with PARP Inhibitors
NA · 1 location(s) · European Institute of Oncology · NCT06785077Azacitidine and Enasidenib in Treating Patients With IDH2-Mutant Myelodysplastic Syndrome
Phase 2 · 3 location(s) · M.D. Anderson Cancer Center · NCT03383575Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders
Phase 2 · 1 location(s) · Masonic Cancer Center, University of Minnesota · NCT03314974TAK-243 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndromes With Increa
Phase 1 · 5 location(s) · National Cancer Institute (NCI) · NCT03816319Long-term Safety and Tolerability of MY008211A Tablets in Patients With Paroxysmal Nocturnal Hemoglobinuria
Phase 2/Phase 3 · 1 location(s) · Wuhan Createrna Science and Technology Co., Ltd · NCT06933914211^At-BC8-B10 Before Donor Stem Cell Transplant in Treating Patients With High-Risk Acute Myeloid Leukemia, Acute Lymph
Phase 1/Phase 2 · 1 location(s) · Fred Hutchinson Cancer Center · NCT03128034RADeep Multicenter European Epidemiological Platform for Patients Diagnosed With Rare Anemia Disorders (RADs)
Phase N/A · 1 location(s) · Hospital Universitari Vall d'Hebron Research Institute · NCT06213402A Phase 1 Study of CG009301 for Injection in Adult Subjects With Recurrent or Refractory Haematological Malignancies
Phase 1 · 3 location(s) · Cullgen (Shanghai),Inc · NCT07347171Study of Ultomiris® (Ravulizumab) Safety in Pregnancy
Phase N/A · 7 location(s) · Alexion Pharmaceuticals, Inc. · NCT06312644Anti-NKG2A Monoclonal Antibody for AML or MDS Patients Undergoing Haploidentical Transplantation
Phase 2 · 2 location(s) · Istituto Clinico Humanitas · NCT06892223HSCT for Patients With Fanconi Anemia Using Risk-Adjusted Chemotherapy
Phase 2 · 3 location(s) · Children's Hospital Medical Center, Cincinnati · NCT02143830High-Altitude Hematology Observation-Stem Cell Transplantation (HALO-SCT)
Phase N/A · 1 location(s) · Yigeng Cao,MD,PhD · NCT07205523Exercise Training and NR Supplementation Trial to Improve Fitness in AYA HCT Survivors
Phase 2 · 3 location(s) · Children's Hospital of Philadelphia · NCT05194397A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patie
Phase 2 · 13 location(s) · Center for International Blood and Marrow Transplant Researc · NCT06859424A Study of Momelotinib in Participants With Low-risk Myelodysplastic Syndrome
Phase 2 · 39 location(s) · GlaxoSmithKline · NCT06847867Alpha/Beta TCD HCT in Patients With Inherited BMF Disorders
Phase 2 · 1 location(s) · Masonic Cancer Center, University of Minnesota · NCT03579875Repurposing Metformin As a Leukemia-preventive Drug in CCUS and LR-MDS
Phase 2 · 1 location(s) · Kirsten Grønbæk · NCT04741945Personalized NK Cell Therapy in CBT
Phase 2 · 1 location(s) · M.D. Anderson Cancer Center · NCT02727803REAL-CARE: Real-world Effectiveness of Iptacopan in Italian Patients With Paroxysmal Nocturnal Hemoglobinuria
Phase N/A · 12 location(s) · Novartis Pharmaceuticals · NCT07229235Haplo-identical Transplantation for Severe Aplastic Anemia, Hypo-plastic MDS and PNH Using Peripheral Blood Stem Cells a
Phase 2 · 1 location(s) · National Heart, Lung, and Blood Institute (NHLBI) · NCT03520647A Post-Marketing Surveillance Study to Assess Safety of Luspatercept in Korean Patients With Myelodysplastic Syndrome or
Phase N/A · 2 location(s) · Bristol-Myers Squibb · NCT06073860
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.